Amgen seeks FDA OK for once-a-month dose of Repatha; Greece lifts ban on drugs exports;

@FiercePharma: USDA, poultry producers warn MN officials to expect bird flu resurgenceFierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article | Follow @EricPFierce

@CarlyHFierce: This date last year, I saved a story on my computer as "GSK Woes." So basically, not much has changed. | Follow @CarlyHFierce

> Greece has lifted its ban on drug exports, put in place when its fiscal woes led some to believe that drug shortages could arise. Story

> Amgen ($AMGN) has filed with the FDA for approval of a single once-per-month 420 mg injection of its new cholesterol fighter Repatha (evolocumab), which currently is available in a single-use 140 mg/mL prefilled autoinjector that requires three subcutaneous injections for a dose of 420 mg. Report

> Eli Lilly ($LLY) is expanding its new innovation center in Cambridge, MA. Story

> Allergan ($AGN) and Perrigo ($PRGO) have gotten approval for their copies of three Mucinex products. Release

Medical Device News

@FierceMedDev: ShiftLab's first device is nearing commercialization. Will it start a low-cost revolution? More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Robotic surgery aspirant receives $4M+ in equity financing. Article | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. Article | Follow @EmilyWFierce

> Startup Velico nabs another $15.5M from BARDA for dried plasma tech. Story

> Nipro to buy partner, heart attack prediction imaging upstart Infraredx. Report

> WSJ: Feds to launch power morcellator probe aimed at FDA. Article

Biotech News

@FierceBiotech: FierceBiotech radio on GSK's latest setback, Kyle Bass' 'truthful irrelevancy,' and Horizon's web presence. More | Follow @FierceBiotech

@JohnCFierce: Four years after a transatlantic slapdown, Merck KGaA will once again seek cladribine OK. Article | Follow @JohnCFierce

@DamianFierce: I hereby endorse this bold, disruptive approach to the language of innovation. More | Follow @DamianFierce

> Lilly upsizes its new Cambridge, MA, R&D shop as Big Pharma crowds the neighborhood. Report

> Soon-Shiong's NantCell hauls in another $100M for immuno-oncology R&D. Story

> FDA advisers side against Purdue's new painkiller, citing dosing dangers. Article

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.